vs

Side-by-side financial comparison of Camden Property Trust (CPT) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $5.3M, roughly 1.0× Camden Property Trust). Camden Property Trust runs the higher net margin — 2954.1% vs -507.8%, a 3461.9% gap on every dollar of revenue. On growth, Camden Property Trust posted the faster year-over-year revenue change (243.0% vs 171.3%). Over the past eight quarters, Camden Property Trust's revenue compounded faster (102.8% CAGR vs 26.8%).

Camden Property Trust is a publicly traded real estate investment trust that invests in apartments in the United States. As of December 31, 2023, the company owned interests in 176 apartment communities containing 59,800 apartment homes in the United States. It is the 14th largest owner of apartments in the United States.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

CPT vs TSHA — Head-to-Head

Bigger by revenue
TSHA
TSHA
1.0× larger
TSHA
$5.5M
$5.3M
CPT
Growing faster (revenue YoY)
CPT
CPT
+71.7% gap
CPT
243.0%
171.3%
TSHA
Higher net margin
CPT
CPT
3461.9% more per $
CPT
2954.1%
-507.8%
TSHA
Faster 2-yr revenue CAGR
CPT
CPT
Annualised
CPT
102.8%
26.8%
TSHA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPT
CPT
TSHA
TSHA
Revenue
$5.3M
$5.5M
Net Profit
$156.0M
$-27.9M
Gross Margin
Operating Margin
-516.0%
Net Margin
2954.1%
-507.8%
Revenue YoY
243.0%
171.3%
Net Profit YoY
283.5%
-48.3%
EPS (diluted)
$1.44
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPT
CPT
TSHA
TSHA
Q4 25
$5.3M
$5.5M
Q3 25
$2.6M
$0
Q2 25
$2.6M
$2.0M
Q1 25
$2.5M
$2.3M
Q4 24
$1.5M
$2.0M
Q3 24
$1.7M
$1.8M
Q2 24
$2.6M
$1.1M
Q1 24
$1.3M
$3.4M
Net Profit
CPT
CPT
TSHA
TSHA
Q4 25
$156.0M
$-27.9M
Q3 25
$108.9M
$-32.7M
Q2 25
$80.7M
$-26.9M
Q1 25
$38.8M
$-21.5M
Q4 24
$40.7M
$-18.8M
Q3 24
$-4.2M
$-25.5M
Q2 24
$42.9M
$-20.9M
Q1 24
$83.9M
$-24.1M
Operating Margin
CPT
CPT
TSHA
TSHA
Q4 25
-516.0%
Q3 25
Q2 25
-1347.1%
Q1 25
-930.5%
Q4 24
-985.8%
Q3 24
-1448.4%
Q2 24
-1915.4%
Q1 24
-713.3%
Net Margin
CPT
CPT
TSHA
TSHA
Q4 25
2954.1%
-507.8%
Q3 25
4246.9%
Q2 25
3063.8%
-1353.6%
Q1 25
1561.0%
-935.2%
Q4 24
2642.3%
-929.0%
Q3 24
-246.3%
-1427.5%
Q2 24
1646.9%
-1882.0%
Q1 24
6533.4%
-705.4%
EPS (diluted)
CPT
CPT
TSHA
TSHA
Q4 25
$1.44
$-0.08
Q3 25
$1.00
$-0.09
Q2 25
$0.74
$-0.09
Q1 25
$0.36
$-0.08
Q4 24
$0.37
$-0.07
Q3 24
$-0.04
$-0.10
Q2 24
$0.40
$-0.09
Q1 24
$0.77
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPT
CPT
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$25.2M
$319.8M
Total DebtLower is stronger
$3.9B
Stockholders' EquityBook value
$4.4B
$246.9M
Total Assets
$9.0B
$343.3M
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPT
CPT
TSHA
TSHA
Q4 25
$25.2M
$319.8M
Q3 25
$25.9M
$297.3M
Q2 25
$33.1M
$312.8M
Q1 25
$26.2M
$116.6M
Q4 24
$21.0M
$139.0M
Q3 24
$31.2M
$157.7M
Q2 24
$93.9M
$172.7M
Q1 24
$92.7M
$124.0M
Total Debt
CPT
CPT
TSHA
TSHA
Q4 25
$3.9B
Q3 25
$3.7B
Q2 25
$3.8B
Q1 25
$3.7B
Q4 24
$3.5B
Q3 24
$3.5B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
CPT
CPT
TSHA
TSHA
Q4 25
$4.4B
$246.9M
Q3 25
$4.5B
$219.0M
Q2 25
$4.6B
$248.7M
Q1 25
$4.6B
$55.1M
Q4 24
$4.7B
$71.5M
Q3 24
$4.7B
$88.8M
Q2 24
$4.9B
$108.9M
Q1 24
$4.9B
$53.8M
Total Assets
CPT
CPT
TSHA
TSHA
Q4 25
$9.0B
$343.3M
Q3 25
$9.1B
$316.6M
Q2 25
$9.1B
$333.3M
Q1 25
$9.0B
$138.4M
Q4 24
$8.9B
$160.4M
Q3 24
$8.9B
$180.2M
Q2 24
$9.1B
$200.4M
Q1 24
$9.1B
$153.0M
Debt / Equity
CPT
CPT
TSHA
TSHA
Q4 25
0.89×
Q3 25
0.82×
Q2 25
0.83×
Q1 25
0.81×
Q4 24
0.75×
Q3 24
0.73×
Q2 24
0.73×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPT
CPT
TSHA
TSHA
Operating Cash FlowLast quarter
$826.6M
$-26.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
5.30×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPT
CPT
TSHA
TSHA
Q4 25
$826.6M
$-26.7M
Q3 25
$250.9M
$-24.2M
Q2 25
$230.7M
$-20.2M
Q1 25
$148.2M
$-22.0M
Q4 24
$774.9M
$-18.3M
Q3 24
$261.6M
$-21.6M
Q2 24
$225.1M
$-21.5M
Q1 24
$135.9M
$-19.8M
Free Cash Flow
CPT
CPT
TSHA
TSHA
Q4 25
Q3 25
$-24.3M
Q2 25
Q1 25
Q4 24
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.7M
Q1 24
$-19.9M
FCF Margin
CPT
CPT
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-905.5%
Q3 24
-1210.9%
Q2 24
-1951.9%
Q1 24
-584.5%
Capex Intensity
CPT
CPT
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
2.0%
Q2 24
18.1%
Q1 24
4.1%
Cash Conversion
CPT
CPT
TSHA
TSHA
Q4 25
5.30×
Q3 25
2.30×
Q2 25
2.86×
Q1 25
3.82×
Q4 24
19.04×
Q3 24
Q2 24
5.24×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons